Prolonged Survival in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressed Metastatic Breast Cancer after Targeted Therapy is Dominantly Contributed by Luminal-Human Epidermal Growth Factor Receptor-2 Population

The prognosis of patients with human epidermal growth factor receptor-2 (HER2)-overexpressed metastatic breast cancer (MBC) has improved drastically following the development anti-HER2 therapies. We question what factors are involved in outcome by treatment. One hundred and two MBC who received chemotherapy were classified into groups according to subtype: luminal/HER2-negative (n = 50), HER2 26), triple-negative subtypes 26). Clinicopathologic features clinical outcomes compared. Disease-free intervals group significantly shorter than those other groups. Age, tumor grade, number disease sites, prior chemotherapeutic regimens did not differ among As a result, median overall survival was longer (114, 68, 18 months, respectively, p < 0.001). To determine key underlying favorable group, further divided subgroups, luminal-HER2 non-luminal-HER2 groups, their hormone receptor status, Median from time diagnosis that (not reached 39 0.048), as shown group. In conclusion, HER2-overexpression receiving therapy considerably luminal-HER2, but